Progression of kidney disease: Blocking leukocyte recruitment with chemokine receptor CCR1 antagonists  by Anders, H.-J. et al.
Progression of kidney disease: Blocking leukocyte
recruitment with chemokine receptor CCR1
antagonists
H-J Anders1, V Ninichuk1 and D Schl +ondorff1
1Nephrological Center, Medical Policlinic, Ludwig Maximilians-University Munich, Munich, Germany
Chronic kidney disease (CKD) is usually associated with
interstitial leukocytic cell infiltrates, which may contribute
to disease progression by production of proinflammatory,
proapoptotic, and profibrotic mediators. Recruiting
leukocytes into the kidney involves local expression of
chemotactic cytokines, that is, chemokines, that interact with
respective chemokine receptors on the leukocyte’s outer
surface. Thus, specific chemokine receptor antagonists may
represent an attractive therapeutic concept to interfere with
renal leukocyte recruitment. Among the proinflammatory
chemokine receptors, chemokine receptor (CCR)-1 has
nonredundant roles for leukocyte adhesion to activated
vascular endothelium and for transendothelial migration. In
fact, blocking CCR-1 with specific small-molecule antagonists
was shown to retard progression in various types of rodent
CKD models. Here we discuss the perspective of CCR-1 as
a new potential target for the treatment of CKD.
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Inflammatory cell infiltrates are a hallmark of chronic kidney
diseases (CKDs). Infiltrating leukocytes produce proinflam-
matory and profibrotic cytokines that contribute to fibroblast
proliferation, myofibroblast transdifferentiation, matrix pro-
duction, and tubular atrophy.1 Recent advances in the
understanding of the molecular mechanisms that regulate
renal leukocyte recruitment suggest chemokines and chemo-
kine receptors as new targets for specific pharmacological
intervention. Chemokine receptors are a family of seven-
transmembrane-spanning G-protein-coupled receptors ex-
pressed on the surface of leukocytes.2 As chemokine receptors
can bind multiple proinflammatory chemokines, therapeutic
blockade of chemokine receptors rather than individual
chemokine ligands may be the preferred strategy in order to
interfere with leukocyte recruitment to sites of tissue injury.
Here we discuss the emerging perspective for therapeutic
blockade of chemokine receptor (CCR)-1 in CKDs.
WHY FOCUS ON CHEMOKINE RECEPTORS?
Upon injury, parenchymal tissues produce inflammatory
mediators that enhance the expression of adhesion molecules
such as selectins and integrins and the presentation of
chemokines at the luminal endothelial cell surface of
capillaries adjacent to the tissue lesion. Selectins mediate
the rolling process of leukocytes along the endothelial surface
by interaction with their respective carbohydrate ligands. The
rolling facilitates the subsequent endothelial–leukocyte inter-
actions through chemokine activation of leukocyte integrins,
resulting in firm binding to their endothelial immunoglobu-
lin–like integrin ligands and adhesion (Figure 1). The
chemokines may either be generated by injured endothelial
cells or by the surrounding tissue and then be transcytosed
across the endothelium by chemokine receptor-like proteins
such as the Duffy antigen-related chemokine receptor
(DARC). The chemokines are then exposed at the luminal
endothelial cell surface on specific glycosaminoglycans such
as heparan sulfate proteoglycans. The interaction of a
chemokine with its corresponding chemokine receptor can
cause conformational changes of the leukocyte integrins,
leading to firm adhesion of the leukocyte to endothelial cells.
The concerted interaction of adhesion molecules, endothelial
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heparan sulfate proteoglycans, and the chemokine system
provides a versatile system that allows for a high degree of
variability, depending on, for example, the specific micro-
vascular bed. In the kidney this is illustrated by the difference
in, for example, glycosaminoglycans, integrins, and selectins
present in the high shear-stress, high-permeability glomeru-
lar microcirculation versus the low shear-stress peritubular
microcirculation (Figure 2). These differences will also
influence chemokine transcytosis (absence of DARC on
glomerular endothelial cells versus presence on peritubular
capillaris) and presentation by the different glycocalyx of
these vascular beds (Figure 2).
Different types of chemokine receptors are expressed in a
restricted manner on specific leukocyte subsets. The picture is
further complicated by the fact that, for example, monocytes
and T-cells will change the type of chemokine receptor that
they express on their cell surface depending on their state of
activation and maturation.3 As multiple chemokine receptors
are involved in adhesion and chemotaxis of the different
leukocyte subsets, it would be desirable to identify those that
have nonredundant functions for recruitment of the immune
cell subsets of interest. In the context of CKD, the leukocyte
subsets of interest include monocytes/macrophages and T
cells.1,4
RATIONALE FOR FOCUSSING ON THE CHEMOKINE RECEPTOR
CCR1
T cells, neutrophils, monocyte/macrophages, and dendritic
cells can express CCR1, which binds multiple proinflamma-
tory chemokine ligands, that are, chemokine ligand (CCL)-3
(macrophage inflammatory protein (MIP)-1a), CCL5
(RANTES), CCL7 (membrane cofactor protein-3), CCL14
hemofiltrate CC chemokine (HCC)-1, CCL15 (HCC-2),
CCL16 (HCC-4), and CCL23 (MIP-3).2 For example, CCL5
immobilized on vascular endothelium induces leukocyte
arrest via CCR1 but not CCR5, while transendothelial
migration is supported by both receptors.5
Thus, CCR1-dependent adhesion represents a proximal
and crucial event in leukocyte adhesion, suggesting that lack
of CCR1 or CCR1 blockade may interfere with leukocyte
recruitment in vivo. In fact, intravital microscopy of the
microcirculation of the cremaster muscle in mice revealed that
leukocyte adhesion and transendothelial migration in re-
sponse to the chemokine CCL3 were markedly reduced in
CCR1-deficient mice or in wild-type mice given a CCR1
antagonist.6 These data indicate an important role for CCR1
in monocyte/macrophage and T-cell adhesion to activated
vascular endothelium, the critical initial step for leukocyte
transmigration, and hence recruitment to extravascular sites
of injury. The relevance of CCR1 for leukocyte extravasation
was also demonstrated in various inflammatory disease
models such as Schistosoma-induced granuloma formation,
cardiac allograft rejection, or renal unilateral ureteral
obstruction.7–9 Furthermore, CCR1 appears to have an
additional nonredundant role in activating macrophages in
a proinflammatory environment.6 Thus, CCR1 has important
functions in leukcoyte adhesion, transendothelial migration,
and activation, which provides a rationale for validating
CCR1 as a therapeutic target in renal disease models.
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Figure 1 | Leukocyte migration from the vascular to the
extravascular compartment. In the vascular compartment, the
rolling leukocyte interacts through P-selectin glycoprotein ligand
with P-selectin on the endothelial surface. Chemokines are produced
by activated vascular endothelial cells and presented at the vascular
lumen by binding to glycosaminoglycans. Chemokines ligate
chemokine receptors on the surface of leukocytes, which activates
integrins (e.g. intercellular adhesion molecule-1) to interact with
adhesion molecules on the endothelial cell surface (e.g. ICAM or
vascular cell adhesion molecule-1).
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Figure 2 | Schematic view of differences in adhesion molecules,
heparin sulfate proteoglycans, and other glycosaminoglycans,
transcytosis and presentation of chemokines (e.g. DARC) on
glomerular and peritubular vascular endothelia.
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CCR1- MEDIATES INTERSTITIAL BUT NOT GLOMERULAR
LEUKOCYTE ACCUMULATION
Compartment-specific recruitment of different leukocyte
populations may involve different glycosaminoglycans and
adhesion molecules (Figure 2), but also different chemokines
and chemokine receptors. For example, in mice with renal
interstitial fibrosis injection of fluorescently labeled mono-
cytes and T cells results in their localization to the renal
interstitium. When CCR1-deficient leukocytes or leukocytes
pretreated with a CCR1 antagonist were used, almost no renal
localization occurred after injection,9 demonstrating the
importance of CCR1 for the recruitment of monocytes and
T cells into the renal interstitial compartment. By contrast,
similar cell transfer studies in mice with immune complex
glomerulonephritis revealed that CCR1 does not participate
in monocyte recruitment into the inflamed glomeruli,10
illustrating that CCR1 mediates the recruitment of leukocytes
to the interstitial but not to the glomerular compartment.
Glomerular leukocyte recruitment may be mediated by other
chemokine receptors such as CCR2 and CCR5.11,12
CCR1 BLOCKADE IMPROVES THE OUTCOME OF VARIOUS
TYPES OF EXPERIMENTAL KIDNEY DISEASE
Human renal biopsy studies have confirmed renal CCR1
expression on macrophages and T cells of predominantly
interstitial inflammatory cell infiltrates in various forms of
kidney diseases.13 Interstitial inflammation is considered to
contribute significantly to the progression of renal diseases.
Thus, to evaluate the contribution of CCR1 to this infiltrate
requires interventional studies with CCR1 antagonists or
with mice made genetically deficient for CCR1 in experi-
mental models of kidney disease.
Unilateral ureteral obstruction in C57BL/6 mice
Unilateral ureteral obstruction is used as a model for
interstitial fibrosis commonly associated with chronic
nephropathies. Within a few days after surgery the inflam-
matory infiltrate of obstructed kidneys express CCR1
messenger ribonucleic acid (mRNA) at high levels compared
to nonobstructed kidneys.14 Injections with BX471, a small-
molecule nonpeptide CCR1 antagonist, markedly reduced
interstitial macrophages and T-cell infiltrates. This was
associated with less tubular injury and interstitial fibrosis,
as determined by interstitial fibroblasts, fibrotic interstitial
volume, and mRNA and protein expression for collagen I.15
Interestingly, the CCR1 antagonist was still effective in
slowing down the process when started at a time point when
substantial interstitial fibrosis was already present. These data
suggest that interfering with interstitial leukocyte recruitment
can prevent or slow down tubular cell injury and interstitial
fibrosis, two major factors for progressive loss of renal
function in CKD.
Lupus-like glomerulonephritis of MRLlpr/lpr mice
MRLlpr/lpr mice are a valuable model of spontaneous immune
complex glomerulonephritis that shares several similarities
with human lupus nephritis. Administration of the CCR1
antagonist to MRLlpr/lpr mice with established kidney disease
reduced the numbers of interstitial macrophages, T cells, and
smooth muscle actin-positive myofibroblasts and diminished
renal tumor growth factor (TGF)-b mRNA expression and
interstitial collagen I deposits.10 The improvement of
histopathological parameters was associated with reduced
blood urea nitrogen levels. Surprisingly, the glomerular
pathology and the number of glomerular macrophages were
not reduced by the CCR1 antagonist, so that proteinuria also
remained unaffected. These data indicate that CCR1-
dependent leukocyte recruitment into the interstitial com-
partment contributes significantly to the progression of renal
failure in MRLlpr/lpr mice. They also show again (see above)
that CCR1 does not appear to be involved in leukocyte
infiltration into the glomerulus and therefore blocking CCR1
does not ameliorate glomerular pathology.
Adriamyin-induced nephrotic syndrome in Balb/c mice
Proteinuria is a prognostic factor for the progression of CKD.
While CCR1 blockade did not have an effect on glomerular
proteinuria in lupus mice, the beneficial effects of CCR1
antagonism might still apply to the tubulointerstitial
pathology associated with nephrotic syndrome. This issue
was addressed by testing the CCR1 antagonist BX471 in the
model of adriamycin-induced focal segmental glomerulo-
sclerosis in Balb/c mice. In this model, glomerulosclerosis is
associated with nephrotic syndrome and progressive inter-
stitial fibrosis. BX471 injections from week 2 to 6 after
induction of the model reduced interstitial macrophage and
T-cell infiltrates as well as interstitial volume and the
numbers of fibroblast-specific protein-1-positive interstitial
fibroblasts.16 Again, glomerular macrophage infiltrates and
proteinuria were not affected by BX471. These data suggest
that CCR1 antagonism can mitigate the progressive inter-
stitial fibrosis associated with nephrotic range proteinuria.
Collagen4 A3-deficient mice as a model for autosomal
recessive Alport syndrome
Collagen4 A3-deficient mice develop CKD similar to human
autosomal recessive Alport syndrome. Interstitial macro-
phages rather than TGF-b-induced fibroblast accumulation
and interstitial matrix deposition cause tubular atrophy and
renal dysfunction in that model.17 A role of interstitial
macrophages for disease progression is also supported by our
study in collagen4 A3-deficient mice treated with BX471
from 6 to 10 weeks of age.6 BX471 increased the mean
survival from 69 days in vehicle-treated collagen4 A3-
deficient mice to 86 days (P¼ 0.0002). This survival benefit
was associated with a reduction of interstitial macrophages,
apoptotic tubular cells, and in morphometric indices of
tubular atrophy, interstitial fibrosis, and peritubular capillary
cross sections. Again proteinuria remained unaltered. Thus,
blocking CCR1-dependent interstitial macrophage recruit-
ment delayed progression of interstitial disease and death
from renal failure in this model of Alport nephropathy.
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Nephropathy of db/db mice with type II diabetes
Recent data provide evidence for a role of inflammatory cells
also in the progression of diabetic nephropathy. Blocking
CCR1 in diabetic nephropathy could address this issue. Male
db/db mice with hyperinsulinemic diabetes develop nephro-
pathy associated with interstitial macrophage infiltrates at
6 month of age.18 Interstitial macrophage recruitment in
db/db mice appears to be CCR1-dependent, as injections
with BX471 from 5 months of age for 10 days reduced
the number of macrophages in the renal interstitium
compared to vehicle-treated db/db mice (unpublished
observation). Whether this will eventually delay the progression
of diabetic nephropathy in this model remains to be
examined.
Kidney allograft dysfunction in rabbits and rats
Cardiac transplant studies in CCR1-deficient mice first
suggested a role for CCR1 in allograft rejection.8 Horuk
et al.19 studied the effects of CCR1 blockade with BX471 on
allograft dysfunction in a model of kidney transplantation in
rabbits. BX471 improved serum creatinine level and renal
survival as compared to placebo-treated rabbits. Further-
more, BX471 was as effective as cyclosporin in preventing
extensive infarction of transplanted kidneys. Another study
addressed the role of CCR1 in chronic allograft nephropathy.
BX471 was given from day 21 to 42 after transplantation of
kidneys from Fischer 344 rats into Lewis rats.20 BX471
reduced the number of ED-1-positive macrophages and the
interstitial fibrosis in the allografts. These data suggest that
CCR1-dependent leukocyte recruitment and activation con-
tributes to acute and chronic allograft nephropathy, and that
blocking CCR1 may have beneficial effects on renal survival
after kidney transplantation.
SUMMARY
CCR1 antagonism with specific small-molecule antagonists
can effectively prevent recruitment of monocytes and T cells
into the renal interstitial compartment. CCR1 blockade
proved to be effective in various types of experimental kidney
disease in rodents even when treatment is initiated after the
disease process is established. It remains to be evaluated
whether CCR1 blockade has additive effects to current
treatments of CKD, for example, blockade of the renin–an-
giotensin system. Clearly, however, glomerular pathology and
proteinuria remain unaffected by CCR1 blockade, so that
chemokine receptors other than CCR1 (e.g. CCR2) may
contribute to glomerular leukocyte infiltration. Based on the
experimental data available, we propose that the therapeutic
effects of CCR1 antagonists – in combination with established
therapies – should be evaluated in an attempt to slow down
the tubulointerstitial component of progressive human
kidney diseases.
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